“The diary 'A life without winter', which collects the true and authentic testimonies of patients with autoimmune hemolytic anemia due to cold antibodies (Cad), an ultra-rare pathology. It is a project perfectly in line with our mission, which is to develop drugs in areas where there is truly an unmet need, therefore first in class, best in class drugs. We have a very clear vision from the company to support patients suffering from these rare diseases. In fact, we want to increase phase 3 studies by 50% and give patients and patient associations a voice.” As Fulvia FilippiniCountry Public Affairs Head, Sanofi Italia, speaking today, in Rome, at the presentation event of the Diary which tells the story of the experiences of patients and caregivers and born from an initiative of the pharmaceutical company in collaboration with FB&Associati with the contribution of Cittadinanzattiva and Uniamo, the Italian federation of rare diseases.
With this initiative “we hope to bring to the attention of the institutions, which have already demonstrated closeness to these testimonies – adds Filippini – 'concrete' issues linked to exemption, disability, difficulty in accessing dedicated centres, which are few. On Sanofi's part there is a very strong commitment to these pathologies” which however “cannot be carried out by us alone, but in collaboration with patient associations, clinicians and caregivers”. Precisely for this reason the company “also constantly works on memoranda of understanding with over 20 patient associations to collaborate jointly towards a common goal” he concludes.
#Rare #diseases #Filipinos #Sanofi #diary #give #voice #autoimmune #hemolytic #anemia #patients
